Bind is pitching at the Investor Event for the Research Ventures Catalyst programme. Find us at the Francis Crick Institute on July 23rd (more information here).

Bind Research is excited to welcome Dr Marcus Harrison as Chief Operating Officer.

Dr Marcus Harrison is an experienced COO with over 15 years in executive roles across life science organisations, including university spinouts, non-profits, and industry ventures. Prior to joining Bind Marcus served as Director of Strategy Delivery and Partnerships at the Usher Institute at the University of Edinburgh, Chief Operating Officer at the Medicines Discovery Catapult (MDC), and before this in executive positions for several start-up and established life science organisations. During the COVID-19 pandemic Marcus established the operational functions at the Alderley Park Lighthouse Lab, helping to scale the UK’s diagnostic capacity. Marcus’s broad expertise in building organisations positions him well to build Bind’s core operational functions encompassing partner engagement, project delivery, impact reporting, risk management and programme governance.

Bind Research is delighted to welcome Melissa Strange in her new role as Chief Financial Officer.

Melissa Strange is a commercially-minded senior finance leader with over 16 years worth of experience in life sciences companies. Melissa has been involved from early-stage research through clinical development and into commercial phases, and has worked across biotech, healthtech and medtech, where she has provided expertise in financial strategy, tax management and has supported a range of commercial and corporate transactions, including significant dilutive and non-dilutive funding. Prior to joining Bind Melissa served as Chief Financial Officer at Infinitopes, Brainomix and Closed Loop Medicine and was VP, Finance for Summit Therapeutics, a NASDAQ listed biotech. Melissa is also Chair of the Finance and Tax Advisory Committee at the BioIndustry Association. Melissa will be overseeing Bind’s financial operations and legal aspects.

Bind is a finalist in the UK Department for Science, Innovation, and Technology (DSIT) Research Ventures Catalyst programme.

By making it through the first round, we received £70,000 in seed funding, which we are using to lay the foundation of a non-profit research institute to target disordered proteins. Successful proposals will be funded by up to £25M from the UK government with a philanthropic match.

Bind is pitching in the UK Department for Science, Innovation, and Technology (DSIT) Research Ventures Catalyst programme at the Royal Society of Chemistry.

Success in the first round guarantees seed funding with which we can build a full proposal for a Focused Research Organisation with the mission of making intrinsically disordered proteins druggable. Successful proposals will be funded by up to £25M from the UK government with a philanthropic match.